What is RU58841?
RU58841 is a nonsteroidal antiandrogen that blocks the effects of androgens like testosterone and dihydrotestosterone (DHT). DHT is a male hormone that causes pattern baldness by attaching itself to the follicle and shrinking it. RU58841 has been found to inhibit DHT, thus stopping hair loss.Male pattern baldness doesn’t occur because of an excessive amount of DHT. Baldness occurs because of a sensitivity to DHT, and so by reducing this sensitivity, hair loss can be slowed down and even halted.
Originally discovered to treat androgen-dependent skin disorders, such as acne, RU58841 has also been found to treat alopecia (hair loss). As things stand (2021), RU58841 can’t be prescribed and sold at any pharmacies, as it has not yet been medically approved.
Does RU58841 Stop Baldness and Regrow Hair?
In studies, scientists saw steady hair growth in patients after only two months. In a study using finasteride, the patients showed a decrease in DHT and an increase in testosterone levels, but the patients that were administered with RU58841 had no significant changes in DHT and testosterone levels.Researchers conclude that 5 percent of topical RU58841 not only induced noticeable effects on hair and follicular regrowth in such a short amount of time, but were also able to continue these effects with persistent use.
What are the negative side-effects of RU58841?
RU58841 hasn't entered phase two of drug development, so it is unknown what side-effects there could be. However, it is also important to note that RU58841 does not only block DHT, but all other androgens including testosterone, so there are likely to be negative side-effects that we can predict.
Interference with the physiologic activities of androgens can lead to side effects such as:
- chest pain
- dizziness
- fatigue
- headaches
- low libido
- impotence
- mood swings
- blurred vision
- feminisation
- breast pain
- breast swelling
RU58841 is not legally available for commercial use, so please do exercise caution if you’re considering using it.
0 comments:
Post a Comment